Cellceutix Provides Update to Shareholders

BEVERLY, MA, Sep 24, 2014 (Marketwired via COMTEX) Cellceutix Corporation (OTCQB: CTIX) (the Company ), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications today has provided an update to its shareholders. My fellow Cellceutix shareholders, As I do periodically, I d like to take a moment to discuss some of our accomplishments over the past year and update everyone on the current position of our company and its portfolio of drugs in development. There is plenty to update as the past twelve months have been a time of substantial growth for Cellceutix and while I am proud of all that we ve accomplished, I am even more excited about the future. Oncology Studies We are now in the ninth cohort of a Phase 1 trial of Kevetrin for advanced solid tumors that is being hosted at Harvard University s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. To briefly recap, Kevetrin is a novel compound that
http://bit.ly/1ohWoTU